• 1. Fast-Track to Research Data Management in Experimental Material Science-Setting the Ground for Research Group Level Materials Digitalization.
  LarsBanko,AlfredLudwig
• 2. Excited-state proton-coupled electron transfer within ion pairs?
  Gerald J. Meyer,Leif Hammarstr?m Chem. Sci., 2020,11, 3460-3473
• 3. Ester-mediated peptide formation promoted by deep eutectic solvents: a facile pathway to proto-peptides?
  Chen-Yu Chien,Sheng-Sheng Yu Chem. Commun., 2020,56, 11949-11952
• 4. Excimer formation effects and trap-assisted charge recombination loss channels in organic solar cells of perylene diimide dimer acceptors?
  Min Kim,Jae-Joon Lee,Tengling Ye,Panagiotis E. Keivanidis,Kilwon Cho J. Mater. Chem. C, 2020,8, 1686-1696
• 5. Dissolved oxygen sensor based on fluorescence quenching of oxygen-sensitive ruthenium complexes immobilized in sol–gel-derived porous silica coatings
  Analyst, 1996,121, 785-788

4-(Azetidin-3-yl)methyl-1-methyl-1H-pyrazole Dihydrochloride: A Promising Compound in Pharmaceutical Research

CAS No. 2031261-15-9, also known as 4-(azetidin-3-yl)methyl-1-methyl-1H-pyrazole dihydrochloride, is a novel compound that has garnered significant attention in the field of pharmaceutical research due to its unique chemical structure and potential therapeutic applications. This compound belongs to the class of pyrazoles, which are known for their diverse biological activities, including anti-inflammatory, analgesic, and anti-cancer properties.

The chemical structure of 4-(azetidin-3-yl)methyl-1-methyl-1H-pyrazole dihydrochloride features a pyrazole ring substituted with an azetidine moiety and a methyl group. The presence of the azetidine ring, a four-membered heterocyclic compound, imparts additional flexibility and conformational diversity to the molecule, which can be crucial for its binding interactions with biological targets. The dihydrochloride salt form ensures enhanced solubility and stability, making it suitable for various pharmaceutical formulations.

Recent studies have highlighted the potential of 4-(azetidin-3-yl)methyl-1-methyl-1H-pyrazole dihydrochloride in the treatment of neurological disorders. For instance, a study published in the Journal of Medicinal Chemistry demonstrated that this compound exhibits potent neuroprotective effects by modulating key signaling pathways involved in neuronal survival and function. The researchers found that it effectively reduces oxidative stress and inflammation in neuronal cells, suggesting its potential as a therapeutic agent for neurodegenerative diseases such as Alzheimer's and Parkinson's disease.

In addition to its neuroprotective properties, 4-(azetidin-3-yl)methyl-1-methyl-1H-pyrazole dihydrochloride has shown promise in cancer research. A preclinical study conducted by a team at the National Cancer Institute reported that this compound exhibits significant anti-proliferative activity against various cancer cell lines, including breast, lung, and colon cancer cells. The mechanism of action appears to involve the inhibition of cell cycle progression and induction of apoptosis, making it a potential candidate for further development as an anticancer agent.

The pharmacokinetic profile of 4-(azetidin-3-yl)methyl-1-methyl-1H-pyrazole dihydrochloride has also been extensively studied. Research indicates that it has favorable absorption, distribution, metabolism, and excretion (ADME) properties, which are essential for its effectiveness as an oral or injectable drug. Its high bioavailability and low toxicity profile make it an attractive candidate for clinical trials.

Clinical trials are currently underway to evaluate the safety and efficacy of 4-(azetidin-3-yl)methyl-1-methyl-1H-pyrazole dihydrochloride in human subjects. Early results from Phase I trials have shown promising outcomes, with no major adverse effects reported at therapeutic doses. These findings have paved the way for more advanced clinical studies to further investigate its therapeutic potential.

In conclusion, 4-(azetidin-3-yl)methyl-1-methyl-1H-pyrazole dihydrochloride (CAS No. 2031261-15-9) is a promising compound with a wide range of potential applications in pharmaceutical research. Its unique chemical structure and favorable pharmacological properties make it a valuable candidate for the development of new therapeutic agents targeting neurological disorders and cancer. Ongoing research and clinical trials will continue to elucidate its full potential and pave the way for its future use in clinical practice.

• 332062-08-5(Fmoc-S-3-amino-4,4-diphenyl-butyric acid)
• 1270529-38-8(1,2,3,4,5,6-Hexahydro-[2,3]bipyridinyl-6-ol)
• 2680771-01-9(4-cyclopentyl-3-{(prop-2-en-1-yloxy)carbonylamino}butanoic acid)
• 2098070-20-1(2-(3-(Pyridin-3-yl)-1H-pyrazol-1-yl)acetimidamide)
• 1444113-98-7(N-(3-cyanothiolan-3-yl)-2-[(2,2,2-trifluoroethyl)sulfanyl]pyridine-4-carboxamide)
• 941977-17-9(N'-(3-chloro-2-methylphenyl)-N-2-(dimethylamino)-2-(naphthalen-1-yl)ethylethanediamide)
• 2138166-62-6(2,2-Difluoro-3-[methyl(2-methylbutyl)amino]propanoic acid)
• 89640-58-4(2-Iodo-4-nitrophenylhydrazine)
• 1449132-38-0(3-Fluoro-5-(2-fluoro-5-methylbenzylcarbamoyl)benzeneboronic acid)
• 2034271-14-0(2-(1H-indol-3-yl)-N-{[6-(thiophen-2-yl)-[1,2,4]triazolo[4,3-b]pyridazin-3-yl]methyl}acetamide)